Showing 1 - 20 results of 31,203 for search '(( third ((mean decrease) OR (_ decrease)) ) OR ( _ ((26 decrease) OR (a decrease)) ))', query time: 0.64s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Third. by Cuicui Liu (1496260)

    Published 2024
    “…It revealed that the total systematic spillover exhibited an initial increase, followed by a subsequent decrease. Notably, the fluctuation in this phenomenon intensified significantly during the epidemic. …”
  6. 6

    Histogram of number of drugs with (a) increased and (b) decreased usage within 12 months. by Nguyen Thach (20347852)

    Published 2024
    “…<p>There are 162 out of 237 PWUDs with an increase and 188 with a decrease in usage of at least one drug.</p>…”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

    Published 2025
    “…Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 185.6, <i>p</i> = 4.8 × 10<sup>−42</sup>, condition: intensity interaction F = 10.37, <i>p</i> = 9.3 × 10<sup>−21</sup>, nested ANOVA (mouse nested within session), condition F = 174, <i>p</i> = 1.5 × 10<sup>−39</sup>, condition: intensity interaction F = 12.7, <i>p</i> = 2 × 10<sup>−26</sup>, post hoc for each level baseline versus repetitive stress <i>p</i> < 0.01 for all levels above 50 dB, all Bonferroni corrected). …”
  12. 12
  13. 13
  14. 14

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”
  15. 15

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  16. 16

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”
  17. 17

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  18. 18

    BrdU incorporation is elevated in clrn1-/- zebrafish at 4 mpf and decreases with age. by Hannah J. T. Nonarath (20861735)

    Published 2025
    “…<p>Anti-BrdU (green) staining in paraffin sections from (a,a’) 4 mpf, (b,b’) 8 mpf, (c,c’) 12 mpf, and (d,d’) 20 mpf in wild-type and <i>clrn1</i><sup><i>-/-</i></sup> zebrafish retinas. …”
  19. 19
  20. 20

    Histograms of the extent of the (a) increase and (b) decrease by the difference in categorical usage within 12 months for all drugs. by Nguyen Thach (20347852)

    Published 2024
    “…<p>Histograms of the extent of the (a) increase and (b) decrease by the difference in categorical usage within 12 months for all drugs.…”